UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023995
Receipt number R000027622
Scientific Title Effect of serotonin-norepinephrine reuptake inhibitor on functional gastrointestinal disorder and evaluation of the brain function.
Date of disclosure of the study information 2016/09/09
Last modified on 2019/09/12 13:21:29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of serotonin-norepinephrine reuptake inhibitor on functional gastrointestinal disorder and evaluation of the brain function.

Acronym

Effect of SNRI on functional gastrointestinal disorder

Scientific Title

Effect of serotonin-norepinephrine reuptake inhibitor on functional gastrointestinal disorder and evaluation of the brain function.

Scientific Title:Acronym

Effect of SNRI on functional gastrointestinal disorder

Region

Japan


Condition

Condition

functional gastrointestinal disorder

Classification by specialty

Medicine in general Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The effect, safety and influence to brain function of SNRI are evaluated in patients with functional gastrointestinal disorders.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

PAGI-SYM:The change in the general score and the lower rank score of PAGI-SYM between a baseline and 6 weeks later of prescription.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The patients in functionality gastrointestinal disease throw duloxetine 20mg to average treatment for 6 weeks.

Interventions/Control_2

The patients in functionality gastrointestinal disease throw PURASEBO to average treatment for 6 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

85 years-old >=

Gender

Male and Female

Key inclusion criteria

Agreement by a document can be acquired from the patient who didn't also admit improvement of the symptom using a curative for the first step which appears on a guideline by functionality dyspepsia or hypersensitive gut syndrome and a checked case from the symptom and an examination in endoscope.

Key exclusion criteria

The case which isn't treated by other anti-depressants.
The case with the medical history of the hyperesthesia.
The case which merges the disease judged to have an influence on the life of the patient.
The case with which I participated in other clinical trials and clinical tests within 6 months before experimental drug prescription.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Rei
Middle name
Last name Wake

Organization

Shimane University Faculty of Medicine

Division name

Department of Psychiatry

Zip code

6938501

Address

89-1 Enya-cho, Izumo, Shimane

TEL

0853-23-2111

Email

rei@med.shimane-u.ac.jp


Public contact

Name of contact person

1st name Rei
Middle name
Last name Wake

Organization

Shimane University Faculty of Medicine

Division name

Department of Psychiatry

Zip code

6938501

Address

89-1 Enya-cho, Izumo, Shimane

TEL

0853-23-2111

Homepage URL


Email

rei@med.shimane-u.ac.jp


Sponsor or person

Institute

Shimane University Faculty of Medicine
Department of Psychiatry

Institute

Department

Personal name



Funding Source

Organization

Shimane University Faculty of Medicine
Department of Psychiatry

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shimane University

Address

89-1 Enya-cho, Izumo city, Shimane

Tel

0853202262

Email

rei@med.shimane-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 11 Month 01 Day

Date of IRB

2015 Year 12 Month 09 Day

Anticipated trial start date

2015 Year 12 Month 10 Day

Last follow-up date

2018 Year 09 Month 28 Day

Date of closure to data entry

2018 Year 09 Month 28 Day

Date trial data considered complete

2018 Year 09 Month 28 Day

Date analysis concluded

2018 Year 09 Month 28 Day


Other

Other related information



Management information

Registered date

2016 Year 09 Month 09 Day

Last modified on

2019 Year 09 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027622


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name